Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-90014496 in adult patients with B-cell non-Hodgkin lymphoma
NL-OMON60223Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1 trial of prizloncabtagene autoleucel in mature B-cell lymphoma and non-Hodgkin lymphoma (NHL), sponsored by Janssen Pharmaceutical. Started Jun 2024; status: active, not recruiting.
02
Drugs
prizloncabtagene autoleucel
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON60223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60223.